|
gptkbp:instanceOf
|
gptkb:biotechnology
gptkb:public_company
|
|
gptkbp:awarded
|
gptkb:German_Future_Prize_2021
|
|
gptkbp:CEO
|
gptkb:Uğur_Şahin
|
|
gptkbp:chairman
|
gptkb:Helmut_Jeggle
|
|
gptkbp:collaboratedWith
|
gptkb:Pfizer
gptkb:Bill_&_Melinda_Gates_Foundation
gptkb:Sanofi
gptkb:Fosun_Pharma
gptkb:Genevant_Sciences
gptkb:Regeneron
gptkb:Genentech
gptkb:Roche
|
|
gptkbp:country
|
gptkb:Germany
|
|
gptkbp:focusesOn
|
infectious diseases
immunotherapy
mRNA therapeutics
|
|
gptkbp:foundedBy
|
gptkb:Uğur_Şahin
gptkb:Özlem_Türeci
gptkb:Christoph_Huber
|
|
gptkbp:foundedYear
|
2008
|
|
gptkbp:headquartersLocation
|
gptkb:Mainz,_Germany
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
BioNTech
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:IPODate
|
2019
|
|
gptkbp:legalForm
|
gptkb:Societas_Europaea_(SE)
|
|
gptkbp:listedOn
|
gptkb:NASDAQ
gptkb:Frankfurt_Stock_Exchange
|
|
gptkbp:marketCap
|
tens of billions USD (2021-2022)
|
|
gptkbp:notableAchievement
|
developed first approved mRNA COVID-19 vaccine
|
|
gptkbp:notableEvent
|
Emergency Use Authorization for COVID-19 vaccine in 2020
WHO Emergency Use Listing for COVID-19 vaccine in 2020
|
|
gptkbp:notableInvention
|
gptkb:mRNA_vaccine_technology
|
|
gptkbp:notableProduct
|
gptkb:BNT162b2
vaccine
|
|
gptkbp:numberOfEmployees
|
over 3,000
|
|
gptkbp:parentCompany
|
gptkb:BioNTech_SE
|
|
gptkbp:researchArea
|
gene therapy
personalized cancer vaccines
protein replacement therapy
small molecule immunomodulators
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:22UA_(Frankfurt)
gptkb:BNTX
|
|
gptkbp:subsidiary
|
gptkb:BioNTech_RNA_Pharmaceuticals_GmbH
gptkb:BioNTech_US_Inc.
|
|
gptkbp:website
|
https://biontech.com
|
|
gptkbp:bfsParent
|
gptkb:Pfizer
|
|
gptkbp:bfsLayer
|
4
|